Forvis Mazars Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.13M Buy
28,316
+1,507
+6% +$324K 0.12% 78
2026
Q1
$5.83M Buy
26,809
+636
+2% +$141K 0.11% 88
2025
Q4
$5.98M Sell
26,173
-91
-0.3% -$20.7K 0.11% 86
2025
Q3
$6.08M Buy
26,264
+1,547
+6% +$315K 0.12% 82
2025
Q2
$4.59M Buy
24,717
+292
+1% +$54.3K 0.1% 91
2025
Q1
$5.12M Buy
24,425
+7,158
+41% +$1.39M 0.12% 83
2024
Q4
$3.07M Buy
17,267
+230
+1% +$42.3K 0.07% 129
2024
Q3
$3.36M Sell
17,037
-8,119
-32% -$1.52M 0.08% 123
2024
Q2
$4.31M Buy
25,156
+8,491
+51% +$1.41M 0.11% 102
2024
Q1
$3.03M Buy
16,665
+1,223
+8% +$211K 0.08% 123
2023
Q4
$2.39M Sell
15,442
-544
-3% -$79.3K 0.07% 138
2023
Q3
$2.38M Sell
15,986
-1,094
-6% -$161K 0.07% 134
2023
Q2
$2.3M Buy
17,080
+6,231
+57% +$914K 0.07% 153
2023
Q1
$1.73M Buy
10,849
+956
+10% +$146K 0.06% 161
2022
Q4
$1.6M Buy
9,893
+52
+0.5% +$7.97K 0.06% 165
2022
Q3
$1.32M Sell
9,841
-212
-2% -$30.4K 0.05% 175
2022
Q2
$1.54M Buy
10,053
+1,110
+12% +$170K 0.06% 152
2022
Q1
$1.45M Buy
8,943
+1,437
+19% +$209K 0.06% 130
2021
Q4
$1.02M Buy
7,506
+349
+5% +$41.2K 0.04% 138
2021
Q3
$772K Sell
7,157
-282
-4% -$32.2K 0.04% 147
2021
Q2
$838K Sell
7,439
-2,683
-27% -$302K 0.04% 138
2021
Q1
$1.09M Sell
10,122
-9,545
-49% -$1.02M 0.05% 129
2020
Q4
$2.11M Buy
19,667
+2,375
+14% +$228K 0.11% 94
2020
Q3
$1.51M Buy
17,292
+2,129
+14% +$200K 0.09% 108
2020
Q2
$1.49M Buy
15,163
+5,968
+65% +$525K 0.1% 105
2020
Q1
$701K Buy
9,195
+1
+0% +$85 0.06% 142
2019
Q4
$814K Buy
9,194
+575
+7% +$47.7K 0.06% 135
2019
Q3
$653K Sell
8,619
-204
-2% -$14K 0.05% 136
2019
Q2
$642K Buy
8,823
+243
+3% +$19.1K 0.05% 138
2019
Q1
$691K Sell
8,580
-306
-3% -$25K 0.06% 131
2018
Q4
$819K Sell
8,886
-36
-0.4% -$3.17K 0.08% 100
2018
Q3
$844K Sell
8,922
-4,877
-35% -$462K 0.07% 108
2018
Q2
$1.28M Sell
13,799
-3,254
-19% -$318K 0.12% 93
2018
Q1
$1.61M Buy
17,053
+1,909
+13% +$210K 0.16% 79
2017
Q4
$1.47M Buy
15,144
+385
+3% +$36.3K 0.15% 82
2017
Q3
$1.31M Sell
14,759
-479
-3% -$36.5K 0.14% 78
2017
Q2
$1.1M Buy
15,238
+1,051
+7% +$70.7K 0.13% 89
2017
Q1
$924K Sell
14,187
-1,463
-9% -$92K 0.11% 87
2016
Q4
$980K Buy
15,650
+786
+5% +$48K 0.13% 82
2016
Q3
$937K Buy
14,864
+475
+3% +$30.8K 0.13% 77
2016
Q2
$891K Sell
14,389
-888
-6% -$54.1K 0.13% 79
2016
Q1
$873K Sell
15,277
-83
-0.5% -$4.63K 0.14% 78
2015
Q4
$910K Sell
15,360
-44
-0.3% -$2.53K 0.14% 79
2015
Q3
$838K Buy
15,404
+2,568
+20% +$167K 0.15% 73
2015
Q2
$862K Buy
12,836
+17
+0.1% +$1.11K 0.13% 83
2015
Q1
$750K Buy
12,819
+799
+7% +$48.3K 0.11% 88
2014
Q4
$787K Sell
12,020
-1,562
-12% -$98.5K 0.13% 80
2014
Q3
$784K Hold
13,582
0.14% 78
2014
Q2
$767K Sell
13,582
-1,107
-8% -$58.1K 0.13% 78
2014
Q1
$758K Sell
14,689
-1,403
-9% -$70.9K 0.13% 88
2013
Q4
$850K Sell
16,092
-252
-2% -$12.4K 0.16% 83
2013
Q3
$731K Sell
16,344
-57
-0.3% -$2.53K 0.15% 85
2013
Q2
$678K Buy
+16,401
New +$717K 0.54% 53

Other funds holding ABBV

Forvis Mazars Wealth Advisors's ABBV Position: Q2 2026 in Review

Forvis Mazars Wealth Advisors increased its AbbVie (ABBV) stake by 5.6% in Q2 2026, buying an estimated $324K and bringing the position to 28,316 shares worth $7.13M. The position accounts for 0.12% of the portfolio, ranked #78.

Forvis Mazars Wealth Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Forvis Mazars Wealth Advisors held 28,316 shares of AbbVie worth $7.13M as of Q2 2026.
  • Forvis Mazars Wealth Advisors bought 1,507 AbbVie shares in Q2 2026, an estimated $324K.
  • AbbVie made up 0.12% of Forvis Mazars Wealth Advisors's portfolio in Q2 2026, its #78 holding.
  • Forvis Mazars Wealth Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.